{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336843","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2026-08-06T12:05:22+00:00","discovered_at":"2026-08-06T12:10:00.478232+00:00","generated_at":"2026-08-06T12:10:35.383335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology Q2 2026 net loss $18.0M; cash $153.4M; refinances debt facility","bullets":["GAAP net loss of $18.0M ($0.13/share) vs $25.9M ($0.49/share) in Q2 2025; non-GAAP net loss $14.3M.","Cash, equivalents and investments $153.4M; sufficient to fund operations through H1 2028.","Refinanced $10M debt with HSBC Ventures; can draw up to additional $20M through June 2028; total facility up to $50M.","Appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.","ASPEN-09-Breast Phase 2 topline data from 80 patients expected mid-2027; ALX2004 safety data expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336843","json":"https://secwatch.observer/filing/0001193125-26-336843.json","markdown":"https://secwatch.observer/filing/0001193125-26-336843.md","text":"https://secwatch.observer/filing/0001193125-26-336843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/0001193125-26-336843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:10:35.383335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}